Business Wire

Technology Innovation Institute’s Directed Energy Research Centre becomes First-in-Region to Replicate Electromagnetic Pulses from High-altitude Nuclear Reaction

18.10.2021 12:28:00 EEST | Business Wire | Press release

Share

Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) today announced that its Directed Energy Research Centre (DERC) has become the first such entity in the region capable of reproducing the high-altitude electromagnetic pulses (HEMP) generated during nuclear reaction in high altitudes at its electromagnetic compatibility (EMC) labs. The Nuclear Electromagnetic Pulse Simulator offers critical infrastructures, service providers, and research institutions in the UAE and wider GCC region greater autonomy when it comes to testing - a function that needed to earlier be outsourced abroad.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005404/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Centre (Photo: AETOSWire)

DERC’s EMC labs comprise a modular semi-anechoic chamber that enables testing to evaluate susceptibility of electronics to electromagnetic pulses while providing the necessary evidence that these comply with international standards.

In partnership with Montena Technologies, a leading Switzerland-based company specialising in the generation and measurement of high-voltage fast transient impulses, simulating natural and human-made electromagnetic phenomena, and a key manufacturer of Nuclear EMP systems, DERC has commissioned a system to replicate the electromagnetic environment generated by a nuclear reaction at high altitudes (more than 40 km above the ground) in the laboratory.

Speaking on the development, Dr. Ray O. Johnson, CEO of Technology Innovation Institute (TII), said: “In line with our ambition to continue to develop breakthrough solutions that drive IP development and facilitate cutting-edge scientific research, this new capability is important. As a leading technology institute in the region, we are committed to building the UAE’s science, technology, and engineering prowess, while leveraging the power of advanced technologies to make our world more secure.”

Dr Chaouki Kasmi, Chief Researcher, Directed Energy Research Centre (DERC), said: “We are delighted to add this capability to DERC’s growing resources of cutting-edge technological solutions that are shaping our future. A Nuclear Electromagnetic Pulse simulator is unique to the GCC region and is crucial for the protection of strategic systems and critical infrastructures.”

DERC and TII can now offer government entities and industry in the UAE, the requisite experimental, numerical, and analytical support to verify accurate hardening of equipment against multiple international standards.

Manufacturers keen to export their products to markets compliant with EMC directives (namely the EU or the United States) and those conforming to IEC requirements on HEMP protection will appreciate the significance of this announcement.

For his part, Werner Hirschi, CEO, Montena Technologies SA, said: “As a global leader in providing equipment for simulation of electromagnetic threats, for the measurement of pulsed electromagnetic quantities and for the transmission of fast pulsed signals in noisy environments, we are pleased to partner with DERC in implementing a unique infrastructure that will trigger the impulse to success. Montena looks forward to a long and fruitful collaboration with TII and is committed to supporting TII in meeting its goal of creating innovation for a better world.”

For more information, visit www.tii.ae
Connect with us on social media:
LinkedIn:
https://www.linkedin.com/company/tiiuae/
Twitter: https://twitter.com/TIIuae
Instagram: https://www.instagram.com/tiiuae/

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Technology Innovation Institute
Hanz Valbuena
comms@atrc.ae

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f

Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye